Verisk Health, a portfolio company of Veritas Capital, has appointed Dr. Emad Rizk as CEO. Previously, Rizk was CEO of Accretive Health Inc.
Waltham, MA, August 15, 2016 — Verisk Health, a leader in data-driven healthcare solutions, today announced that Dr. Emad Rizk has been named Chief Executive Officer (CEO).
Dr. Emad Rizk is a seasoned and renowned healthcare industry senior executive with over 25 years of experience working closely with Payers and Government entities. Dr. Rizk joins Verisk Health from Accretive Health, Inc. where he served as CEO and as a member of its Board of Directors. Prior to Accretive Health, he was President at McKesson Health Solutions, a business that provides clinical and financial solutions to most of the Healthcare Payers. He is also a regular lecturer at Wharton, Harvard, MIT, Columbia, and Kellogg.
“Dr. Emad Rizk has a long and successful track record in the healthcare industry with relevant Payer experience leading businesses like Verisk Health. He shares our vision of delivering the strongest value proposition to customers through innovation and outstanding service. We are confident in his ability to drive the Company forward as we move into a new chapter as a standalone business focused on proprietary data analytics in key vertical markets,” said Ramzi Musallam, CEO and Managing Partner at Veritas Capital, which owns Verisk Health.
Dr. Emad Rizk stated, “I am honored by the opportunity to serve as CEO of this exceptional analytics company. Verisk Health is one of the most respected analytics organizations in the healthcare industry. As commercial Payers and Government entities explore ways to improve performance and lower costs, I believe Verisk Health is well positioned to be their partner of choice. I look forward to leveraging my Payer experience and working closely with our talented team and valued partners at Veritas Capital to maintain the company’s strong culture and momentum. We are a high growth organization committed to solidifying our identity and leadership as a standalone company and to advancing and innovating our data services, analytics, and technologies for the benefit of all our customers.”
Additional Background on Emad Rizk, MD
Before joining McKesson (MCK), Dr. Rizk served as Senior Partner and Global Director, Medical Management/Pharmacy for Deloitte Consulting. While at Deloitte, he led the company’s medical cost and quality management practice across all segments. Prior to that, he served as the Associate Medical Director and then Worldwide Medical Director at the Monsanto Corporation. Dr. Rizk currently serves as a board member at Intarcia, Inc., Accuray Inc. (ARAY), and the National Association for Hispanic Health. He also previously served on the National Clinical Advisory Board, National Quality Review Board, and was Director on the board of DMAA (The Care Continuum Alliance). Dr. Rizk’s work has been widely published in journals and books.
Dr. Rizk has been widely recognized in the healthcare Industry. Modern Healthcare has named Dr. Rizk numerous times as one of the “50 Most Influential Physician Executives in the United States,” and the “Top 100 Most Powerful People in Healthcare”. Managed Healthcare Executive named him to its “Top 25 Leaders in Disease Management.”
About Verisk Health
Verisk Health is transforming the business of healthcare by providing data services, analytics, and advanced technologies that answer the industry’s most complex challenges with a focus on identifying and reducing risk across all domains of healthcare. Verisk Health’s broad analytical solution suite is designed to help health plans and other risk-bearing entities improve quality, reduce costs, ensure risk adjusted revenue, pay claims accurately, and support compliance. From effective population risk assessment and stratification, quality reporting, revenue accuracy, and fraud, waste, and abuse, Verisk Health is committed to answering the unique challenges of its clients. For more information, please visit www.veriskhealth.com.